<p>Nuvation Bio Inc.（紐約證券交易所代碼：NUVB - 獲取免費報告）的股票在週二交易量強勁，此前該公司宣佈季度收益超出預期。當天交易了 6,780,232 股，較前一交易日的 5,075,067 股增加了 34%。該股最後交易價格為$4.5760，之前收盤價為$5.17。</p>
<p>該公司報告季度每股收益（EPS）為（$0.16），超出市場共識預期的（$0.17）$0.01。該季度的收入為 1312 萬美元，而分析師預期為 748 萬美元。Nuvation Bio 的淨利潤率為負的 1413.43%，股本回報率為負的 46.14%。</p>
<h2>分析師評級調整</h2>
<p>幾位股票分析師最近對 NUVB 股票發佈了報告。Citizens Jmp 將 Nuvation Bio 的目標價從$6.00 上調至$8.00，並在週二的研究報告中給予該股 “市場表現優於大盤” 的評級。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了 Nuvation Bio 的 “賣出（d-）” 評級。Wall Street Zen 在 8 月 17 日的研究報告中將 Nuvation Bio 的評級從 “賣出” 上調至 “持有”。加拿大皇家銀行在 8 月 8 日的研究報告中將 Nuvation Bio 的目標價從$6.00 上調至$7.00，並給予該股 “表現優於大盤” 的評級。最後，花旗集團在週二的研究報告中重申了 Nuvation Bio 的 “市場表現優於大盤” 評級。一位研究分析師給予該股 “強烈買入” 評級，七位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Nuvation Bio 目前的平均評級為 “適度買入”，共識目標價為$8.43。</p>
<p><strong>閲讀我們對 Nuvation Bio 的最新分析</strong></p>
<h2>內部人士買賣</h2>
<p>在其他 Nuvation Bio 的新聞中，內部人士 Gary Hattersley 在 10 月 27 日（星期一）出售了 100,000 股該公司的股票。股票以平均價格$5.02 出售，總價值為$502,000.00。該交易已在證券交易委員會的備案中披露，您可以通過此鏈接訪問。29.93% 的股票由公司內部人士持有。</p>
<h2>Nuvation Bio 的機構交易</h2>
<p>幾位大型投資者最近增加或減少了對該公司的持股。Millennium Management LLC 在第一季度將其在 Nuvation Bio 的持股增加了 52.4%。Millennium Management LLC 目前擁有 3,774,003 股該公司的股票，價值$6,642,000，在此期間又購買了 1,298,131 股。Natixis 在第二季度獲得了 Nuvation Bio 的新頭寸，價值$1,766,000。Marshall Wace LLP 在第二季度獲得了 Nuvation Bio 的新頭寸，價值$1,699,000。Geode Capital Management LLC 在第二季度將其在 Nuvation Bio 的持股增加了 16.8%。Geode Capital Management LLC 目前擁有 5,994,798 股該公司的股票，價值$11,691,000，在上個季度又購買了 864,194 股。最後，AWM Investment Company Inc.在第一季度獲得了 Nuvation Bio 的新頭寸，價值$1,144,000。61.67% 的股票由機構投資者持有。</p>
<h2>Nuvation Bio 股價下跌 12.0%</h2>
<p>該股市值為 15.6 億美元，市盈率為-7.15，貝塔係數為 1.48。該公司的 50 日移動平均線為$3.68，200 日移動平均線為$2.75。該公司的債務與股本比率為 0.13，速動比率為 9.38，流動比率為 9.39。</p>
<h2>Nuvation Bio 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Nuvation Bio Inc 是一家臨牀階段的生物製藥公司，專注於腫瘤治療候選藥物的開發。該公司的主要產品候選藥物是 NUV-868，一種 BD2 選擇性口服小分子 BET 抑制劑，能夠表觀遺傳學調節控制腫瘤生長和分化的蛋白質，包括 c-myc 等癌基因；NUV-1156，一種 AR 結合劑 Xtandi，針對晚期前列腺癌，具有進入通常通過手術前列腺切除術治療的早期階段的潛力；以及藥物 - 藥物結合（DDC）平台，利用抗癌療法藥物結合類中的新型治療方法，將抗癌藥物輸送到癌細胞，以及 NUV-1176，一種 PARP 抑制劑，針對 ER+ 乳腺癌和卵巢癌。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Nuvation Bio</li>
<li>成長投資：您應該在 2022 年採用這種投資策略嗎？</li>
<li>英特爾的 SambaNova 計劃不是收購，而是突襲</li>
<li>如何利用分析師評級進行交易</li>
<li>為什麼 Roblox 股票在第三季度下跌後可能飆升 75%</li>
<li>關於 Markup 計算器</li>
<li>亞馬遜與蘋果：哪隻 Mag 7 更值得購買？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 在 Nuvation Bio 嗎？</h2>
<p>在您考慮 Nuvation Bio 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Nuvation Bio 並不在名單上。</p>
<p>雖然 Nuvation Bio 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NUVB

<p>Nuvation Bio Inc.（紐約證券交易所代碼：NUVB）在報告季度收益超出預期後，交易量激增，成交量達到 678 萬股。該公司公佈的每股收益為（$0.16），超出預期，收入為 1312 萬美元，亦超出預期。分析師的評級各不相同，其中一位給予 “強烈買入”，七位給予 “買入”，一位給予 “賣出”。該股目前下跌 12%，市值為 15.6 億美元。Nuvation Bio 專注於開發腫瘤治療藥物，包括其主要候選藥物 NUV-868</p>

<p>Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) saw strong trading volume on Tuesday after the company announced better than expected quarterly earnings. 6,780,232 shares were traded during trading, an increase of 34% from the previous session's volume of 5,075,067 shares.The stock last traded at $4.5760 and had previously closed at $5.17.</p>
<div class="lb-trans"><p>Nuvation Bio Inc.（紐約證券交易所代碼：NUVB - 獲取免費報告）的股票在週二交易量強勁，此前該公司宣佈季度收益超出預期。當天交易了 6,780,232 股，較前一交易日的 5,075,067 股增加了 34%。該股最後交易價格為$4.5760，之前收盤價為$5.17。</p>
</div><p>The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $13.12 million for the quarter, compared to analysts' expectations of $7.48 million. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%.</p>
<div class="lb-trans"><p>該公司報告季度每股收益（EPS）為（$0.16），超出市場共識預期的（$0.17）$0.01。該季度的收入為 1312 萬美元，而分析師預期為 748 萬美元。Nuvation Bio 的淨利潤率為負的 1413.43%，股本回報率為負的 46.14%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several equities analysts have recently issued reports on NUVB shares. Citizens Jmp lifted their price objective on shares of Nuvation Bio from $6.00 to $8.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Tuesday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Nuvation Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 17th. Royal Bank Of Canada lifted their target price on shares of Nuvation Bio from $6.00 to $7.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, August 8th. Finally, Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of Nuvation Bio in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Nuvation Bio presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $8.43.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 NUVB 股票發佈了報告。Citizens Jmp 將 Nuvation Bio 的目標價從$6.00 上調至$8.00，並在週二的研究報告中給予該股 “市場表現優於大盤” 的評級。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了 Nuvation Bio 的 “賣出（d-）” 評級。Wall Street Zen 在 8 月 17 日的研究報告中將 Nuvation Bio 的評級從 “賣出” 上調至 “持有”。加拿大皇家銀行在 8 月 8 日的研究報告中將 Nuvation Bio 的目標價從$6.00 上調至$7.00，並給予該股 “表現優於大盤” 的評級。最後，花旗集團在週二的研究報告中重申了 Nuvation Bio 的 “市場表現優於大盤” 評級。一位研究分析師給予該股 “強烈買入” 評級，七位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Nuvation Bio 目前的平均評級為 “適度買入”，共識目標價為$8.43。</p>
</div><p><strong>Read Our Latest Analysis on Nuvation Bio</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Nuvation Bio 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the business's stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. 29.93% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Nuvation Bio 的新聞中，內部人士 Gary Hattersley 在 10 月 27 日（星期一）出售了 100,000 股該公司的股票。股票以平均價格$5.02 出售，總價值為$502,000.00。該交易已在證券交易委員會的備案中披露，您可以通過此鏈接訪問。29.93% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of Nuvation Bio</h2>
<div class="lb-trans"><h2>Nuvation Bio 的機構交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock worth $6,642,000 after buying an additional 1,298,131 shares during the period. Natixis acquired a new position in Nuvation Bio during the 2nd quarter valued at $1,766,000. Marshall Wace LLP acquired a new position in Nuvation Bio during the 2nd quarter valued at $1,699,000. Geode Capital Management LLC raised its stake in Nuvation Bio by 16.8% during the 2nd quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company's stock valued at $11,691,000 after purchasing an additional 864,194 shares during the last quarter. Finally, AWM Investment Company Inc. acquired a new position in Nuvation Bio during the 1st quarter valued at $1,144,000. 61.67% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾位大型投資者最近增加或減少了對該公司的持股。Millennium Management LLC 在第一季度將其在 Nuvation Bio 的持股增加了 52.4%。Millennium Management LLC 目前擁有 3,774,003 股該公司的股票，價值$6,642,000，在此期間又購買了 1,298,131 股。Natixis 在第二季度獲得了 Nuvation Bio 的新頭寸，價值$1,766,000。Marshall Wace LLP 在第二季度獲得了 Nuvation Bio 的新頭寸，價值$1,699,000。Geode Capital Management LLC 在第二季度將其在 Nuvation Bio 的持股增加了 16.8%。Geode Capital Management LLC 目前擁有 5,994,798 股該公司的股票，價值$11,691,000，在上個季度又購買了 864,194 股。最後，AWM Investment Company Inc.在第一季度獲得了 Nuvation Bio 的新頭寸，價值$1,144,000。61.67% 的股票由機構投資者持有。</p>
</div><h2>Nuvation Bio Trading Down 12.0%</h2>
<div class="lb-trans"><h2>Nuvation Bio 股價下跌 12.0%</h2>
</div><p>The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.15 and a beta of 1.48. The company's 50 day moving average is $3.68 and its 200 day moving average is $2.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.38 and a current ratio of 9.39.</p>
<div class="lb-trans"><p>該股市值為 15.6 億美元，市盈率為-7.15，貝塔係數為 1.48。該公司的 50 日移動平均線為$3.68，200 日移動平均線為$2.75。該公司的債務與股本比率為 0.13，速動比率為 9.38，流動比率為 9.39。</p>
</div><h2>Nuvation Bio Company Profile</h2>
<div class="lb-trans"><h2>Nuvation Bio 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.</p>
<div class="lb-trans"><p>Nuvation Bio Inc 是一家臨牀階段的生物製藥公司，專注於腫瘤治療候選藥物的開發。該公司的主要產品候選藥物是 NUV-868，一種 BD2 選擇性口服小分子 BET 抑制劑，能夠表觀遺傳學調節控制腫瘤生長和分化的蛋白質，包括 c-myc 等癌基因；NUV-1156，一種 AR 結合劑 Xtandi，針對晚期前列腺癌，具有進入通常通過手術前列腺切除術治療的早期階段的潛力；以及藥物 - 藥物結合（DDC）平台，利用抗癌療法藥物結合類中的新型治療方法，將抗癌藥物輸送到癌細胞，以及 NUV-1176，一種 PARP 抑制劑，針對 ER+ 乳腺癌和卵巢癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Nuvation Bio</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>Intel's SambaNova Play Isn't an Acquisition, It's an Ambush</li>
<li>How to trade using analyst ratings</li>
<li>Why Roblox Stock Could Soar 75% After the Q3 Dip</li>
<li>About the Markup Calculator</li>
<li>Amazon vs. Apple: Which Mag 7 Is the Better Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Nuvation Bio</li>
<li>成長投資：您應該在 2022 年採用這種投資策略嗎？</li>
<li>英特爾的 SambaNova 計劃不是收購，而是突襲</li>
<li>如何利用分析師評級進行交易</li>
<li>為什麼 Roblox 股票在第三季度下跌後可能飆升 75%</li>
<li>關於 Markup 計算器</li>
<li>亞馬遜與蘋果：哪隻 Mag 7 更值得購買？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nuvation Bio Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 在 Nuvation Bio 嗎？</h2>
</div><p>Before you consider Nuvation Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Nuvation Bio 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Nuvation Bio 並不在名單上。</p>
</div><p>While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Nuvation Bio 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Nuvation Bio（NYSE:NUVB）因盈利超預期而交易量強勁